A device for treating anaphylaxis.
The MDI with specific actuator orifices and formulation enhances epinephrine delivery to the larynx and lungs, addressing the inefficiencies of existing inhalers by providing rapid and reliable treatment of anaphylaxis with fewer doses and no orientation dependence.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- コクア ファーマ インコーポレイテッド
- Filing Date
- 2026-02-26
- Publication Date
- 2026-06-09
AI Technical Summary
Existing epinephrine inhalers for treating anaphylaxis are not as effective or reliable as intramuscular injections, and there is a need for improved metered-dose inhalers (MDIs) that can deliver epinephrine more rapidly, efficiently, and consistently to the larynx, pharynx, and lungs to treat anaphylaxis effectively.
A metered-dose inhaler (MDI) with an actuator having orifices of specific diameters and a formulation containing epinephrine or a pharmaceutically acceptable salt, along with a liquefied propellant and cosolvent, is designed to deliver epinephrine more effectively to the larynx, pharynx, and lungs, reducing reliance on orientation and minimizing delivery to the oral cavity.
The MDI provides rapid and reliable delivery of epinephrine to the therapeutic areas, reducing the number of doses needed and ensuring consistent treatment of anaphylaxis symptoms within minutes, independent of orientation, and eliminating the need for bulky adapters.
Smart Images
Figure 2026094267000001_ABST